Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Farmers Insurance
Johnson and Johnson
Accenture
Colorcon
Chubb
Citi
Cipla
Harvard Business School

Generated: December 13, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR EXELON

« Back to Dashboard

Clinical Trials for Exelon

Trial ID Title Status Sponsor Phase Summary
NCT00000174 Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx) Completed Novartis Phase 3 This phase IIIb trial is a prospective, randomized, double-blind, placebo-controlled, 36-month study comparing the length of time of progression from mild cognitive impairment (MCI) to a clinical diagnosis of Alzheimer's disease (AD) in subjects taking Exelon vs. placebo. Exelon is currently under review with the U.S. Food and Drug Administration as a treatment for Alzheimer's disease. The drug has been cleared for marketing in more than 40 countries for Alzheimer's disease to date, including all 15 member states of the European Union, New Zealand, Argentina, Brazil and Mexico. Each subject with MCI will be randomly assigned to treatment with either Exelon or placebo. Subjects assigned to Exelon will receive 1.5 to 6.0 mg bid (twice daily) (3.0 to 12 mg/day) for the majority of the study. At every regular visit scheduled every three months, patients will be given basic efficacy and safety assessments. These assessments will include evaluation of adverse events, vital signs, activities of daily living, and clinical staging scales to determine if the subject may have converted to dementia.
NCT00024531 Lipitor as a Treatment for Alzheimer's Disease Completed Pfizer Phase 2 The purpose of this study is to assess the clinical benefit of Lipitor, a cholesterol-lowering drug, in the treatment of Alzheimer's disease.
NCT00024531 Lipitor as a Treatment for Alzheimer's Disease Completed Institute for the Study of Aging (ISOA) Phase 2 The purpose of this study is to assess the clinical benefit of Lipitor, a cholesterol-lowering drug, in the treatment of Alzheimer's disease.
NCT00051909 Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease Completed Eli Lilly and Company Phase 2 Study of an investigational medication for the treatment of Alzheimer's Disease in patients who are not taking Aricept, Reminyl, Exelon.
NCT00105105 Mifepristone as Adjunctive Therapy in Alzheimer's Disease Terminated Institute for the Study of Aging (ISOA) Phase 2 The purpose of this study is to evaluate the effects of C-1073 (Mifepristone) on cognition in patients with Alzheimer's disease (AD) who are also taking an acetylcholinesterase inhibitor (Aricept, Exelon or Reminyl).
NCT00105105 Mifepristone as Adjunctive Therapy in Alzheimer's Disease Terminated Corcept Therapeutics Phase 2 The purpose of this study is to evaluate the effects of C-1073 (Mifepristone) on cognition in patients with Alzheimer's disease (AD) who are also taking an acetylcholinesterase inhibitor (Aricept, Exelon or Reminyl).
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Exelon

Condition Name

Condition Name for Exelon
Intervention Trials
Alzheimer's Disease 10
Alzheimer Disease 5
Mild Cognitive Impairment 2
Healthy 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Exelon
Intervention Trials
Alzheimer Disease 16
Dementia 6
Cognition Disorders 4
Parkinson Disease 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Exelon

Trials by Country

Trials by Country for Exelon
Location Trials
United States 107
China 10
Germany 10
Canada 6
France 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Exelon
Location Trials
Texas 7
New York 7
California 7
Pennsylvania 6
Florida 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Exelon

Clinical Trial Phase

Clinical Trial Phase for Exelon
Clinical Trial Phase Trials
Phase 4 10
Phase 3 6
Phase 2 4
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Exelon
Clinical Trial Phase Trials
Completed 23
Terminated 2
Not yet recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Exelon

Sponsor Name

Sponsor Name for Exelon
Sponsor Trials
Novartis Pharmaceuticals 6
Novartis 4
Inha University Hospital 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Exelon
Sponsor Trials
Other 36
Industry 18
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Colorcon
Medtronic
Julphar
Boehringer Ingelheim
US Army
QuintilesIMS
AstraZeneca
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.